

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC.,
Petitioner,

v.

BAUSCH HEALTH IRELAND LIMITED,
Patent Owner.

Case No. IPR2022-01102 - Patent No. 9,610,321
Case No. IPR2022-01103 - Patent No. 9,616,097
Case No. IPR2022-01104 - Patent No. 9,919,024
Case No. IPR2022-01105 - Patent No. 9,925,231

DECLARATION OF GRAHAM BUCKTON, PH.D.

TABLE OF CONTENTS

| | <u>Page</u> |
|--------------------------------------------------------------------------------------------------------------|-------------|
| I. QUALIFICATIONS..... | 1 |
| II. SCOPE OF WORK | 4 |
| III. LEGAL PRINCIPLES..... | 6 |
| IV. OVERVIEW OF THE CHALLENGED PATENTS | 9 |
| A. Claims of the '231 Patent | 14 |
| B. Claims of the '097 Patent | 15 |
| C. Claims of the '024 Patent | 18 |
| D. Claims of the '321 Patent | 23 |
| E. Claim Comparison..... | 27 |
| F. Prosecution Histories..... | 29 |
| 1. The '231 and '024 patents | 31 |
| 2. The '097 Patent | 31 |
| 3. The '321 Patent | 37 |
| V. THE LEVEL OF ORDINARY SKILL IN THE ART..... | 40 |
| VI. CLAIM TERMS..... | 41 |
| VII. THE STATE OF THE ART | 43 |
| VIII. ASSERTED REFERENCES DISCLOSE OR SUGGEST EACH OF THE CLAIMED FEATURES OF THE CHALLENGED PATENTS..... | 53 |
| A. Asserted Reference Summaries..... | 53 |
| 1. Shailubhai..... | 53 |
| 2. Remington | 55 |

| | |
|---------------------------------------------------------------|-----|
| 3. Mihranyan | 56 |
| 4. Aulton | 56 |
| 5. The 2009 Abstract | 56 |
| 6. Doelker | 57 |
| 7. Zimmer | 58 |
| 8. Camilleri..... | 59 |
| 9. Currie | 60 |
| B. Each Challenged Claim Was Obvious from the Prior Art | 60 |
| 1. The '231 Patent | 61 |
| 2. The '097 Patent | 117 |
| 3. The '024 Patent | 141 |
| 4. The '321 Patent | 175 |
| IX. SECONDARY CONSIDERATIONS | 198 |
| X. CONCLUDING STATEMENTS | 205 |
| XI. APPENDIX – LIST OF EXHIBITS | 206 |

I, Graham Buckton, declare as follows:

I. QUALIFICATIONS

1. I am an Emeritus Professor of Pharmaceutics of the UCL School of Pharmacy of the University of London. I was employed at the School of Pharmacy of the University of London from 1988 to 2015, initially as Lecturer, then Senior Lecturer, Reader and Professor. I served as the Head of the Department of Pharmaceutics between January 2001 and April 2007. I served as Chair of the Master of Sciences in Pharmacy (MPharm) Exam Board between 2002 and 2012. I have been an MPharm (or Bachelors in Pharmacy, BPharm) Examiner at Queens University of Belfast, Cardiff University, University of Nottingham, Kings College, University of Colombo in Sri Lanka, Robert Gordon University, and the University of East Anglia. I received my Ph.D. in Pharmaceutics from Kings College London in 1985.

2. In addition to my academic experience, I have extensive practical experience in formulation development. In 2000 I founded a contract services company called Pharmaterials Ltd. I sold the majority stake to a U.S. company, Pharmaceutics International Inc. (PII), in 2008 and the remaining stake in 2012, at which time I exited. I was Chief Executive Officer from 2000-2012. Pharmaterials carried out materials characterisation, salt selection, polymorph screening, pre-

formulation, formulation development, assay development, clinical trials, and manufacturing.

3. I served on the Committee on Safety of Medicines (CSM), which is the body in the United Kingdom that grants (and revokes) marketing authorizations (the equivalent of the FDA in the US), and I chaired its Chemistry, Pharmacy and Standards (CPS) sub-committee. I remain a member of CPS of the Commission on Human Medicines (a renamed version of CSM). I have been a member of the British Pharmacopoeia Commission and have been a member of working parties for the European and the United States Pharmacopoeias.

4. I have consulted in the fields of physical form and formulation development for companies in Europe, USA, and India.

5. My research has focused on investigating the behaviour of pharmaceutical materials. Applications of my research include studies of surface interactions, adaptation of physical properties of powders by crystallisation and physical manipulation such as milling, and the preparation of drug dosage forms including solid oral-dosage forms and inhalation dosage forms. I also organised the Royal Pharmaceutical Society of Great Britain (RPSGB) course on Tableting Technology every year between 1989-2004, and invited industrial colleagues to assist with the teaching. I gave many lectures during the period as organiser and

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.